Journal article
Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn’s Disease: A Post Hoc Analysis of the IM-UNITI Trial
Abstract
BACKGROUND: This post hoc analysis aimed to evaluate the impact of BMI on the efficacy of ustekinumab in the IM-UNITI study.
METHODS: The relationship between body mass index (BMI) and efficacy of ustekinumab was evaluated using data from a 44-week maintenance study of ustekinumab in Crohn's disease (IM-UNITI, NCT01369355, YODA #2019-4105). The primary endpoints of interest were clinical remission (CR), defined as Crohn's disease activity index …
Authors
Wong ECL; Marshall JK; Reinisch W; Narula N
Journal
Inflammatory Bowel Diseases, Vol. 27, No. 6, pp. 848–854
Publisher
Oxford University Press (OUP)
Publication Date
May 17, 2021
DOI
10.1093/ibd/izaa214
ISSN
1078-0998